Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study

Cytomegalovirus (CMV) is a major cause of infectious complications following cardiac transplantation, severely affecting short- and long-term outcomes. A 12-month, multicenter, randomized, open-label study in de novo cardiac transplant patients was undertaken to compare the efficacy, renal function,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Viganò, Mario (VerfasserIn) , Dengler, Thomas (VerfasserIn) , Mattei, M. F.. (VerfasserIn) , Poncelet, A. (VerfasserIn) , Vanhaecke, J. (VerfasserIn) , Vermes, E. (VerfasserIn) , Kleinloog, R. (VerfasserIn) , Li, Y. (VerfasserIn) , Gezahegen, Y. (VerfasserIn) , Delgado, J. F. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 January 2010
In: Transplant infectious disease
Year: 2010, Jahrgang: 12, Heft: 1, Pages: 23-30
ISSN:1399-3062
DOI:10.1111/j.1399-3062.2009.00448.x
Online-Zugang:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1399-3062.2009.00448.x
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-3062.2009.00448.x
Volltext
Verfasserangaben:M. Viganò, T. Dengler, M.F. Mattei, A. Poncelet, J. Vanhaecke, E. Vermes, R. Kleinloog, Y. Li, Y. Gezahegen, J.F. Delgado, on behalf of the RAD A2411 Study Investigators
Beschreibung
Zusammenfassung:Cytomegalovirus (CMV) is a major cause of infectious complications following cardiac transplantation, severely affecting short- and long-term outcomes. A 12-month, multicenter, randomized, open-label study in de novo cardiac transplant patients was undertaken to compare the efficacy, renal function, and safety of everolimus plus reduced cyclosporine versus mycophenolate mofetil (MMF) plus standard cyclosporine (ClinicalTrials.gov NCT00150046).
Beschreibung:Gesehen am 05.09.2023
Beschreibung:Online Resource
ISSN:1399-3062
DOI:10.1111/j.1399-3062.2009.00448.x